Abstract: A system and a method for controlling an electronic device embedded in a package of a consumer product are disclosed. In one aspect, the consumer product packaging includes a bottle for a beverage, a memory, a receiver and a circuit. The memory stores an action to be performed in response to an input. The receiver receives the input indicative of movement of the bottle. The circuit retrieves the action stored in memory upon receipt of the input and command an electronic communication module to perform the action at a particular time or in a particular sequence.

Abstract: Providing a state of desired effects (SDES) simultaneously on one or more presentation devices using a system having one or more switchers, each switcher having a unique identification code, activation parameters that control when the switcher is operable to send activation signals, and one or more triggers. Each trigger has a trigger identification code associated with a set of one or more presentation devices or associated with another switcher and another trigger, and triggering criteria relating to an occurrence of a particular event. One method includes activating a first switcher, receiving, at the activated first switcher, event information indicative of the occurrence of a particular event, determining if the event information meets triggering criteria for a trigger of the first switcher, and in response to the event information meeting triggering criteria for a trigger of the first switcher, activating the trigger of the first switcher that meets the triggering criteria.

Abstract: A system and a method for controlling an electronic device embedded in a package of a consumer product are disclosed. In one aspect, the consumer product packaging includes a bottle for a beverage, a memory, a receiver and a circuit. The memory stores an action to be performed in response to an input. The receiver receives the input indicative of movement of the bottle. The circuit retrieves the action stored in memory upon receipt of the input and command an electronic communication module to perform the action at a particular time or in a particular sequence.

Abstract: A system and a method for controlling an electronic device embedded in a package of a consumer product are disclosed. In one aspect, the consumer product packaging includes a bottle for a beverage, a memory, a receiver and a circuit. The memory stores an action to be performed in response to an input. The receiver receives the input indicative of movement of the bottle. The circuit retrieves the action stored in memory upon receipt of the input and command an electronic communication module to perform the action at a particular time or in a particular sequence.

Abstract: The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. A?-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.

Abstract: An active agent that causes an increase in the number of disease-associated microglia (DAM) for use in treating a neurodegenerative disease is provided.

Abstract: The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. A?-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.

Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.

Abstract: The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. A?-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.

Abstract: A method of upregulating an anti-inflammatory response in a central nervous system (CNS) of a subject in need thereof is disclosed. The method comprising locally administering to the CNS of the subject a therapeutically effective amount of IFN-beta, thereby upregulating the anti-inflammatory response in the CNS of the subject. Methods of treating an inflammation in a CNS or treating a disease, disorder, condition or injury of a CNS of a subject are also disclosed.

Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.

Abstract: A system and a method for controlling an electronic device embedded in a package of a consumer product are disclosed. In one aspect, the consumer product packaging includes a bottle for a beverage, a memory, a receiver and a circuit. The memory stores an action to be performed in response to an input. The receiver receives the input indicative of movement of the bottle. The circuit retrieves the action stored in memory upon receipt of the input and command an electronic communication module to perform the action at a particular time or in a particular sequence.

Abstract: Systems, methods and apparatus are disclosed for database generation of synchronized actions. In one aspect a method is provided for generating a database of data items indicative of synchronized actions. The method includes determining a set of devices for execution of a storyboard. The set of devices includes packaging of a consumer product. The storyboard relates to promotion of the consumer product. The method further includes generating the storyboard. The storyboard includes a set of actions for the devices. The storyboard includes a set of interrelated actions that form a message for communication to an audience. The method further includes generating data items. The data items correspond to the actions of the storyboard. At least a portion of the data items include time synchronization information for the set of actions. The method further includes storing the data items and the time synchronization information relating to the storyboard in the database.

Abstract: The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. A?-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.

Abstract: The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average molecular weight in the range 13,500 to 18,500 daltons, (ii) 13% to 38% of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68% of the polypeptides have a molecular weight between 7,000 and 41,000 daltons. In an embodiment, the average molecular weight is 16,000 daltons. The invention also provides a method of treating a human subject afflicted with a neurodegenerative disease comprising administering to the human subject a therapeutically effective amount of any of the disclosed compositions so as to thereby treat the human subject.

Abstract: The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average molecular weight in the range 13,500 to 18,500 daltons, (ii) 13% to 38% of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68% of the polypeptides have a molecular weight between 7,000 and 41,000 daltons. In an embodiment, the average molecular weight is 16,000 daltons, and processes for preparing and its uses.

Abstract: Oligosaccharides, and in particular disaccharides, which are degradation products of chondroitin sulfate proteoglycan are effective for use in treating, inhibiting, or ameliorating the effects of injuries or diseases or disorders that result in or are caused by neuronal degeneration or of disorders resulting in mental and cognitive dysfunction. They are also useful for promoting neurogenesis.

Abstract: The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average molecular weight in the range 13,500 to 18,500 daltons, (ii) 13% to 38% of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68% of the polypeptides have a molecular weight between 7,000 and 41,000 daltons. In an embodiment, the average molecular weight is 16,000 daltons, and processes for preparing and its uses.

Abstract: The invention provides a new nerve-derived transglutaminase enzyme that converts immune-derived IL-2 to dimeric IL-2 having oligodendrocyte cytotoxic activity. Both the nerve-derived transglutaminase and the dimeric mammalian, e.g. human, IL-2, are for use as active ingredients in pharmaceutical compositions for inducing and facilitating regeneration of injured nerves of the central nervous system in mammals.

Abstract: Administration of tumor necrosis factor to the site of injured central nervous system axons will result in facilitation of the regeneration of axons across the site of the injury. Recombinant human tumor necrosis factor is the preferred substance for such use.